Download Free Drug Discovery In Japan Book in PDF and EPUB Free Download. You can read online Drug Discovery In Japan and write the review.

This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Sets forth the history, state of the science, and future directions of drug discovery Edited by Jie Jack Li and Nobel laureate E. J. Corey, two leading pioneers in drug discovery and medicinal chemistry, this book synthesizes great moments in history, the current state of the science, and future directions of drug discovery into one expertly written and organized work. Exploring all major therapeutic areas, the book introduces readers to all facets and phases of drug discovery, including target selection, biological testing, drug metabolism, and computer-assisted drug design. Drug Discovery features chapters written by an international team of pharmaceutical and medicinal chemists. Contributions are based on a thorough review of the current literature as well as the authors' firsthand laboratory experience in drug discovery. The book begins with the history of drug discovery, describing groundbreaking moments in the field. Next, it covers such topics as: Target identification and validation Drug metabolism and pharmacokinetics Central nervous system drugs In vitro and in vivo assays Cardiovascular drugs Cancer drugs Each chapter features a case study, helping readers understand how science is put into practice throughout all phases of drug discovery. References at the end of each chapter serve as a gateway to groundbreaking original research studies and reviews in the field. Drug Discovery is ideal for newcomers to medicinal chemistry and drug discovery, providing a comprehensive overview of the field. Veterans in the field will also benefit from the perspectives of leading international experts in all aspects of drug discovery.
Natural Products and Drug Discovery: An Integrated Approach provides an applied overview of the field, from traditional medicinal targets, to cutting-edge molecular techniques. Natural products have always been of key importance to drug discovery, but as modern techniques and technologies have allowed researchers to identify, isolate, extract and synthesize their active compounds in new ways, they are once again coming to the forefront of drug discovery. Combining the potential of traditional medicine with the refinement of modern chemical technology, the use of natural products as the basis for drugs can help in the development of more environmentally sound, economical, and effective drug discovery processes. Natural Products & Drug Discovery: An Integrated Approach reflects on the current changes in this field, giving context to the current shift and using supportive case studies to highlight the challenges and successes faced by researchers in integrating traditional medicinal sources with modern chemical technologies. It therefore acts as a useful reference to medicinal chemists, phytochemists, biochemists, pharma R&D professionals, and drug discovery students and researchers. - Reviews the changing role of natural products in drug discovery, integrating traditional knowledge with modern molecular technologies - Highlights the potential future role of natural products in preventative medicine - Supported by real world case studies throughout
"A lot of hard-won knowledge is laid out here in a brief but informative way. Every topic is well referenced, with citations from both the primary literature and relevant resources from the internet." Review from Nature Chemical Biology Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed ‘too early’ to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest. Each chapter broadly discusses an important topic in drug development, from preclinical work in assay design through clinical trial design, regulatory issues and marketing assessments. After the practical overview provided here, the reader is encouraged to consult more detailed texts on specific topics of interest. "I would actually welcome it if this book’s intended audience were broadened even more. Younger scientists starting out in the drug industry would benefit from reading it and getting some early exposure to parts of the process that they’ll eventually have to understand. Journalists covering the industry (especially the small startup companies) will find this book a good reality check for many an over-hopeful press release. Even advanced investors who might want to know what really happens in the labs will find information here that might otherwise be difficult to track down in such a concentrated form."
Recognizing that a capacity to innovate and commercialize new high-technology products is increasingly a key for the economic growth in the environment of tighter environmental and resource constraints, governments around the world have taken active steps to strengthen their national innovation systems. These steps underscore the belief of these governments that the rising costs and risks associated with new potentially high-payoff technologies, their spillover or externality-generating effects and the growing global competition, require national R&D programs to support the innovations by new and existing high-technology firms within their borders. The National Research Council's Board on Science, Technology, and Economic Policy (STEP) has embarked on a study of selected foreign innovation programs in comparison with major U.S. programs. The "21st Century Innovation Systems for the United States and Japan: Lessons from a Decade of Change" symposium reviewed government programs and initiatives to support the development of small- and medium-sized enterprises, government-university- industry collaboration and consortia, and the impact of the intellectual property regime on innovation. This book brings together the papers presented at the conference and provides a historical context of the issues discussed at the symposium.
Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process. This book provides thoughtful and valuable discussions and analysis of the social challenges and potential opportunities through all stages of the pharmaceutical process, from inception through marketing. With a unique focus on the social factors that increasingly play a role in how drug development is planned, structured, and executed throughout the drug product lifecycle, this is an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society. - Organized in a sequence of interrelated theories and principles that provide the foundation for increased understanding of the relevant social aspects - Includes analysis of important new advances, key scientific and strategic issues, and overviews of recent progress in drug development - Provides a global perspective with examples from developed areas, such as the US, Japan, Canada and Europe, as well as faster-growing and emerging economies including Brazil, Russia, India, and China - Serves as an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
Die Suche nach Medikamenten mit neuen oder verbesserten Eigenschaften hat das Interesse am pharmazeutischen Potenzial von Kohlenhydraten enorm verstärkt. Dies gilt insbesondere für die Entwicklung von Antibiotika, Impfstoffen und Anti-Krebs-Mitteln. Carbohydrate-based Drug Discovery stellt mit mehr als 50 Beiträgen der weltweit führenden Experten die neuesten Entwicklungen in der Kohlenhydrat- und Biochemie vor. Dabei liegt der Schwerpunkt der Darstellung auf der pharmazeutischen Anwendung. In jüngster Zeit sind wirksame, auf Kohlenhydraten basierende Medikamente gegen HIV, Grippe, Epilepsie, Diabetes und Krebs auf den Markt gekommen bzw. werden in Studien klinisch erprobt. Doch das gesamte Potenzial dieser Substanzklasse kann man bislang wohl nur erahnen. Die pharmazeutische Industrie investiert bereits große Summen in die Forschung und Entwicklung. So kommt dieses Handbuch genau zur richtigen Zeit. Umfassend und kompetent behandelt es den gesamten Bereich der Kohlenhydratchemie. Es führt ein in die chemische Synthese, in Biosynthese und Metabolismus und informiert über die Analyse und die zellulären Funktionen von Kohlenhydraten. Einen weiteren Schwerpunkt bildet die Entwicklung von Medikamenten auf Kohlenhydrat-Basis, wie z.B. synthetischer Impfstoffe oder Thrombosemittel auf Basis synthetischer Oligosaccharide. Erschlossen wird das mit einem umfangreichen bibliographischen Anhang versehene Werk durch einen thematischen Index. Sein Herausgeber, Chi-Huey Wong, hat bereits mehrere internationale Preise für sein wissenschaftliches Werk erhalten, darunter den "Presidential Award" und den "Presidential Young Investigator Award".
Silicon (Si) plays a significant role in the resistance of plants to multiple stresses including biotic and abiotic stresses. Silicon is also the only element that does not damage plants when accumulated in excess. However, the contribution of Si to plant growth has been largely ignored due to its universal existence in the earth's crust. From numerous intensive studies on Si, initiated in Japan about 80 years ago, Japanese scientists realized that Si was important for the healthy growth of rice and for stability of rice production. In a worldwide first, silicon was recognized as a valuable fertilizer in Japan. The beneficial effects of Si on rice growth in particular, are largely attributable to the characteristics of a silica gel that is accumulated on the epidermal tissues in rice. These effects are expressed most clearly under high-density cultivation systems with heavy applications of nitrogen. Si is therefore recognized now as an ''agronomically essential element'' in Japan.Recently, Si has become globally important because it generates resistance in many plants to diseases and pests, and may contribute to reduced rates of application of pesticides and fungicides. Silicon is also now considered as an environment-friendly element. The achievements of Si research in Japan are introduced in this book, in relation to soils, fertilizers and plant nutrition.